AKBA vs FOLD vs PTGX vs CYCN vs ANIP

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 3x forward), making it the more compelling value choice. Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, ANI Pharmaceuticals, Inc.

is actually cheaper at 9. 3x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +271. 1%, compared to -93. 5% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: PTGX returned +788. 6% versus CYCN's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 354% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, CYCN leads at 91. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 3x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 31. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 170. 3% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +788. 6% 10Y return). Both have compounded well over 10 years (PTGX: +788. 6%, AKBA: -82. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKBA is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; CYCN is a small-cap quality compounder stock; ANIP is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.